Doctors across the United States are sounding a serious alarm about ketamine safety risks. A drug once reserved for hospital operating theatres is now landing on doorsteps via post, often after nothing more than a brief online questionnaire. The American Society of Anesthesiologists (ASA) updated its guidance this month, pressing policymakers to act before the consequences grow worse.

A Booming Market Outrunning Safety Standards

The US ketamine market has already surpassed $5 billion. Analysts project it to nearly triple within the next decade. Clinics offering ketamine infusions for depression and post-traumatic stress disorder (PTSD) have opened at speed across the country. At the same time, telehealth companies now prescribe the drug after short online consultations and deliver it straight to patients’ homes.

That expansion has left patient safety standards struggling to keep up. Anaesthesiologists are watching the trend with growing unease.

Hospitals have used ketamine for anaesthesia and sedation for decades. Researchers and clinicians have also found promising results when using it off-label for mental health conditions, including treatment-resistant depression and PTSD in military veterans. The science holds real promise. The delivery model, however, does not.

Ketamine Safety Risks: When Convenience Turns Dangerous

The ketamine dangers at home are not theoretical. Last year, a 41-year-old New York woman sought relief from depression through a telehealth service. The company prescribed at-home ketamine despite her disclosing that she also took Xanax. The US Food and Drug Administration warns that combining the two can cause fatal breathing problems. She died.

ASA President Patrick Giam, M.D., FASA, put it plainly: “You can move very quickly from feeling relaxed to becoming deeply sedated, and without proper monitoring and supervision, this can become dangerous. I am concerned that without stronger regulation, we risk repeating another opioid-like public health crisis, particularly because many people underestimate the potential dangers of ketamine.”

Anaesthesiologists point to three ketamine safety risks that make close medical supervision essential:

• Breathing complications: Ketamine can slow or stop breathing, especially at higher doses or alongside other medications.
• Cardiovascular instability: The drug can trigger sudden and dangerous spikes in blood pressure and heart rate.
• Misuse and diversion: Without proper safeguards, patients or others may misuse, share, or illegally resell the drug, or combine it with other substances.

Hospitals administer ketamine with continuous monitoring, trained staff, and immediate access to emergency equipment. None of that exists in a patient’s living room.

Calls for Regulation Grow Louder

The Texas Medical Board recently proposed rules to tighten oversight of ketamine clinics and medical facilities. The ASA responded formally, though it stopped short of endorsing the proposals. It pushed for stronger measures instead.

ASA guidance states that doctors should only administer intravenous, intramuscular, or subcutaneous ketamine for mental health treatment when a physician is physically present and ready to intervene immediately. A video call does not meet that standard. The ASA is explicit on that point.

Georgia, Missouri, and Utah have each introduced bills to strengthen patient protections against the ketamine dangers at home. Advocates say progress at a federal level remains slow.

Questions Every Patient Should Ask First

Anyone considering ketamine therapy should speak with their own physician before committing to treatment. Ask how the drug will come into the room, who will stay to monitor you throughout, and what the plan is if something goes wrong.

“You can go from a short online screening to receiving a powerful anaesthetic at home,” said Dr Giam. “If something goes wrong, there may be no one there trained to respond. In the hospital, we track every milligram. At home, ketamine faces far less scrutiny.”

The ASA’s message is straightforward. Commercial growth should not outrun patient safety. With ketamine safety risks now linked to real fatalities and a $5 billion market still accelerating, regulators face a narrowing window to act.

Source: dbrecoveryresources